MeiraGTx Holdings PLC MGTX:NASDAQ

MeiraGTx Holdings (MGTX), a clinical stage gene therapy company, reported Wednesday a Q3 diluted net loss of $0.59 per share, compared with a $0.17 loss a year earlier.

Analysts polled by Capital IQ expected a GAAP loss of $0.51.

Revenue for the quarter was $6.95 million, up from $5.01 million a year ago.

Analysts expected $2.4 million.

The company said it expects to file an investigational new drug application for AAV-GAD for the treatment of Parkinson's disease during Q4 2021.

MeiraGTx plans to start later stage clinical studies for AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia in 2022 with Janssen

A phase 3 trial of AAV-RPE65 for patients with RPE65-associated retinal dystrophy is slated for early 2022.

Price: 20.10, Change: -0.05, Percent Change: -0.25